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The unified approach to chronic kidney disease (CKD) as per
the Kidney Disease Outcomes Initiative (KDOQI) guideline for
the definition and classification of kidney disease provided a
paradigm shift in the detection, evaluation, and stratification
of what was a neglected clinical problem. The guideline,
based on the then-available evidence, determined the
problems, limitations, and gaps in the knowledge of the
proposed approach. Since then, solutions to the identified
problems have been sought, resolutions are in place or are
forthcoming, and longitudinal and cohort studies have been
undertaken to better define the epidemiology of the disease
and its prognostic determinants. The guideline also fostered
considerable debate on the precision of the glomerular
filtration rate equations, the implications of mislabeling
cases, and the large estimates of prevalent cases of CKD.
Winearls and Glassock now propose a new staging of CKD,
centered on its progression to end-stage renal disease. A
systematic analysis of the data accrued, since the publication
of the original guideline in 2002, is necessary for the
consideration of any refinement or redesign of the current
staging. The Kidney Disease: Improving Global Outcomes
(KDIGO) has undertaken that initiative. There is no need for a
rush to judgment.
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The publication on dissecting and refining the staging of
chronic kidney disease (CKD) in this issue of Kidney
International is part of a series of thoughtful articles
published by two eminent nephrologists in the past year.1–5
As acknowledged by the authors, this article reiterates their
earlier-expressed concerns with the current classification of
CKD, but now with a bold twist, proposes a new definition
and staging of the disease.1 This is a challenging and serious
departure from the zeal with which they have earlier raised
legitimate questions about the Kidney Disease Outcomes
Initiative (KDOQI) definition and staging of CKD.6 The
article fails to acknowledge that since their publication in
2002, the KDOQI definition and classification of CKD were
reviewed at two international conferences convened by the
Kidney Disease: Improving Global Outcomes (KDIGO),
which, after acknowledgment and consideration of the very
concerns expressed by the authors, recommended some
modifications but no change in the classification.7,8 In
addition, plans are underway for a third KDIGO contro-
versies conference in October 2009 for examining the issues
of concern, the need for refinement, and, if necessary, even
redesigning the staging of CKD based on new data on the
subject.
Moreover, it should be noted that the original KDOQI
guideline identified, discussed, and defined the limitations
and problems associated with its proposed staging.6 In fact,
the very studies cited by the authors, and many more, were
prompted by the gaps in knowledge identified in the KDOQI
guideline. Furthermore, and prompted by the issues
identified in the KDOQI guideline, the laboratory assay of
creatinine is now completing standardization worldwide,9
and studies are underway to validate and refine the formulae
for calculating the estimated glomerular filtration rate
(eGFR).10 Essentially, the limitations of the KDOQI classi-
fication were recognized from the outset, and the challenges
they present were defined in the original publication.6 Since
then, solutions to identified problems have been sought,
longitudinal and cohort studies of CKD have been under-
taken, and resolutions are now either in place or are
forthcoming.10–13 As a result, information on the epidemiol-
ogy, course, morbidity, and mortality of CKD in 2009 is in a
much better state of knowledge than it was before 2002. None
of these initiatives, advances, and accomplishments is
acknowledged or mentioned in this article.1 The original
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KDOQI classification made best use of the data that were
available then.6 As new evidence accrues, the present
classification may have to be refined and perhaps even
modified. However, any such change must be data driven and
based on a systematic analysis of the new evidence accrued
since 2002, not a rush to judgment.
BACKGROUND
The KDOQI guideline proposed staging not as an end but as
a beginning to detect individuals at an increased risk and
those affected by kidney injury or loss of function,
irrespective of diagnosis, or whether their disease was stable
or progressive. As recommended in the guideline, diagnosis
and progress would be determined by additional clinical
information during the work-up and follow-up of those
affected by what is a heterogeneous condition with a variable
course in individual cases. Importantly, the staging was used
to develop a public health model for CKD, with a suggested
action plan for each stage. In any such conceptual model,
early detection is essential. In fact, when staging was first
being considered, it was for the early detection of cases
headed to end-stage renal disease and for the evidence of the
high prevalence of cardiovascular disease (CVD) in them.14,15
The need for extension to earlier stages of kidney injury and
loss of function became evident subsequently based on the
data analyzed for the guideline, and provided the basis of a
public health approach to CKD.6,8 The diagram of the public
health model that was originally published has been
modified,16,17 and was the subject of a commentary in
Kidney International16 (Figure 1). The modified course shows
the potential for reversibility at various stages (due either to
treatment or the natural history of the disease) and presents
CVD as a separate and prominent outcome of CKD
(Figure 1). A visual limitation of any diagram based on
arrows is the failure to present the fact that progression or
regression from any stage is not universal, and that many
remain stable at a given stage, at which their CKD neither
progresses nor regresses. This fact was noted in the text of the
KDOQI guideline and has been documented since.6,12,15 Any
interpretation of the staging or the public health model of
CKD, to the contrary and rigidly, is an error of the user and
not the staging or the model.
Another purpose of the KDOQI definition and classifica-
tion of CKD was to improve communication and enhance
the conduct of research. The acceptance and success of the
KDOQI classification in this regard has been most rewarding
and gratifying. At the cost of being repetitious, suffice to say
that none of the references quoted in the proposed redesign
article would have been available without the gaps of
knowledge identified in the original guideline. The CKD
definition and classification have been incorporated into the
ICD9 and are now part of the parlance of medicine. A
PubMed search shows that, of the indexed articles for the
term CKD in 2008, 17% were in non-nephrology journals; in
descending order these were in cardiology, internal medicine,
hypertension, pharmacology, diabetes, gastroenterology,
endocrinology, hematology, and radiology journals (personal
data). Before rushing to judgment at the cost of confusing
our medical and public audience with a new definition and
classification, let us consider the principal dissatisfactions
expressed with the current classification.1
A DISEASE?
The designation of disease inferring that the identified
property conveys some material disadvantage (survival,
morbidity) is a truism. The data substantiating this truism
for CKD classification, presented in the original guideline,
have been substantiated since.13,14,18,19 The concerns expressed
about the use of disease in the KDOQI guideline are perhaps
best addressed in a book on nosography by Knud Farber
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Figure 1 | Conceptual model of the course and outcomes of chronic kidney disease. The ellipses represent the potential changing
stages and consequences of chronic kidney disease (CKD). The first two open ellipses are antecedents and determinants of the increased
risk for CKD. The next two ellipses are flagged for albuminuria and an estimated glomerular filtration rate of o60 ml/min per 1.73 m2, the
two determinants for the definition and detection of CKD. The green ellipse at the top refers to complications that can develop at each
stage of CKD (hypertension, anemia, mineral, and bone disorders) and their treatment (drug side effects). The gradually increasing thickness
of the blue arrows connecting the ellipses represent the relative risk of the potential for progression and that of potential complications.
The dotted blue arrows connecting the ellipses indicate the potential for improvements in albuminuria and glomerular filtration rate,
because of treatment or variable natural history of the primary kidney disease. The thicker red arrows at the bottom indicate the increasing
risk for all-cause mortality, principally because of cardiovascular disease; and their relative sizes represent the increasing risks of death at
each progressive stage of CKD. The figure fails to show that many cases fail to progress or regress and remain at the same stage as when
first detected. GFR, glomerular filtration rate. Reprinted with permission from reference 16.
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(1862–1956). In this historical but thoughtful analysis, Farber
quotes one of the founders of the classification system,
Ottomar Rosenbach (1851–1907), stating, ‘The diagnosis of
the disturbances of diseased organs, which is aimed by the
predominant pathologico-anatomical school, provides an
apparently convenient classification of diseases, but it causes
the greatest difficulties to the person who is to cure the
disease as it only indicates the rough changes in the tissues,
that is, the permanent changes. But in chronic diseases it
must above all be the object to recognize the disease in its
very first stage, that is, the incipient functional disorder.’20
Nephrology is fortunate that its organ of interest, the kidney,
allows for relatively simple measurements (urinalysis, eGFR) of
its ‘incipient functional disorder.’ Not to capitalize on this
major asset and to refine and improve its assessment tools for
clinical use would be a disservice to the science of medicine and
for our very obligation to patients. It can be argued that these
can be studied without being a part of staging. They certainly
can, but then they would go under-diagnosed and remain
unrecognized clinically, as they had been in the past. To walk
away from their clinical use, and their continued evaluation,
refinement, and study would not be the best line of action.
Particularly relevant in this regard is the exclusion of
‘microalbuminuria’ from consideration in the proposed
redesign of CKD staging.1 Needless to say, the cause of
microalbuminuria is worthy of further study and refinement,
but where do the lessons learned from diabetic nephropathy fit
in the scheme of CKD staging? The argument has been made
for a similarity of risk of microalbuminuria to that of cholesterol
and CVD. This is not really accurate. A major difference is that
microalbuminuria, whether due to a localized or generalized
abnormality of the vasculature, is a reflection of glomerular
capillary permeability, that is, it has affected the organ of
interest. This is in sharp contrast to that of cholesterol, which, in
and by itself, is not an indication of any cardiac or vascular
abnormality, although it is associated with and contributes to
the consequent onset of heart and vascular disease. Importantly,
and from a public health perspective, the lesson to recall is that
cardiology never walked away from cholesterol but capitalized
on it. It went on to explore its relationship with CVD,
investigate its pathogenesis, and develop and promulgate its
early treatment for preventing CVD. Attributing microalbumi-
nuria to a generalized vascular abnormality and not using it
clinically in nephrology is to relinquish its present and future
study to cardiology and endocrinology.21
GFR ESTIMATES
Another expressed concern is the validity and accuracy of the
eGFR prediction equations. That is not unique to any
mathematically derived formula, which can be improved by
expanding the database from which it is derived. To a great
extent, that is the story of science and all current
measurement tools. Furthermore, it is important to empha-
size that all glomerular filtration rate (GFR) values are
ultimately estimates and to heed the advice of a founding
father of nephrology and the one who developed the concept
of renal clearance, Homer Smith (1895–1962). In his classic,
The Kidney: Structure and Function in Health and Disease he
states, ‘Absolute values of renal clearance are not highly
significant except when they are the average of several
consecutive periods (3 is a good number), and even in the
same individual the average clearances must be interpreted
with caution pertinent to the interpretation of biostatistical
data of any kind.’ The same caution needs to be applied to
any and all estimates of GFR.10
Single values of eGFR in labeling CKD are not only
contrary to the KDOQI definition of CKD, but when
interpreted in isolation, are fraught with error. Their use in
cross-sectional studies is not the same as that of their clinical
use in a single patient. This is particularly pertinent to the
early stages of CKD (KDOQI stages 1 and 2). Thus, a diabetic
with micoalbuminuria, whose eGFR decreases over time from
128 to 69 ml/min per 1.73 m2, would not fulfill the criteria for
CKD in the proposed new CKD staging system (Table 1,
Reference 1), despite a significant loss of kidney function.
AGING
Another expressed concern is the effect of aging on GFR. The
prediction equations correct the GFR for age but, similar to
actual clearance measurements, show a decline of the GFR with
aging. There are also structural changes of the kidney that
occur with age. The association between age-related structural
changes and declining GFR, although conceptually likely,
remains to be elucidated. Nevertheless, the very criteria set in
the redesigned definition and staging of CKD (structural
changes coupled with functional decline in kidney function)
seems to occur in the elderly.1 How can changes in GFR with
aging then be attributed to the ‘effects of normal ageing’22 or to
a ‘natural decrease in eGFR with aging? Where is the database
of this generalization? Or, should elderly individuals with
reduced or declining eGFR be biopsied to satisfy the structural
requirement of the proposed new CKD staging system1?
The United States renal data service (USRDS) data on
Medicare individuals, 65 years or older clearly show a
significant increase in morbidity of the elderly in the presence
of CKD, which increases with age and with the stage of
CKD.23 This observational data have been confirmed in other
studies, but where is the evidence to the contrary that a
decreasing GFR is normal or natural? Moreover, if so, why
does it not affect all elderly individuals? Once again, at the
very least, we need to study these individuals more carefully
before dismissing the structural and functional changes of
their kidneys as owing to ‘normal ageing’. A simple lesson to
recall here is that learned from the evolution of the
classification system of hypertension. A more intricate
example is that of the classification of Alzheimer’s disease,
which affects principally the elderly. The criteria for the
diagnosis of Alzheimer’s disease have been recently revised to
include the earlier stages of the disorder that are now possible
to detect using new testing methods.24,25
To introduce new criteria for the elderly and to use age-
matched centiles of eGFR in defining reduced kidney
Kidney International (2009) 75, 1015–1018 1017
G Eknoyan: CKD classification p u b l i c f o r u m
function is against the very advice of the Renaissance genius,
Leonardo da Vinci (1452–1519), who stated that ‘Simplicity is
the ultimate sophistication.’ The simplicity of the current
classification very likely accounts for its widespread accep-
tance and adoption. Simplicity should remain a goal and
unnecessary complexity must be avoided in any redesign of
the classification system.
PREVALENCE OF CKD
Another expressed concern is the large estimates of CKD
population. At the cost of exaggerating, because of the
expressed disbelief,1 it may be worth citing the report on the
four moons of Jupiter by Galileo (1564–1642), considered a
founding father of science. The astonishment by most and
the belief of the Church at the time did not detract from their
study and the subsequent discovery of the other moons of
Jupiter, all of which were there all along but never observed
before. In this regard, the characterization of CKD as an
epidemic based on prevalent cases should be qualified,
because these individuals, just like the moons of Jupiter, were
there all along but went unrecognized and were neglected by
health care providers and planners. Only prospective data on
incident cases can document the epidemic proportions of any
disease. Under any circumstance, these individuals need to be
detected, observed, studied, and, where necessary, treated
rather than be excluded and dismissed because of their vast
numbers and the burden they would be to nephrologists.1 As
more data become available, prognostic criteria would help
characterizing these individuals better, but to exclude from
detection, as the current conceptual model of CKD allows
(Figure 1) may not be a responsible line of action.
CONCLUSIONS
We have come a long way in understanding kidney disease
and have expanded the reaches of our discipline in a relatively
short period of time, since the publication of the original
CKD classification. To redesign the staging of CKD to
accommodate nephrocentric purists would be a mistake. It
would be a regression to the beginning days of nephrology,
when much of it was driven and focused on end-stage renal
disease. Importantly, it would be an abandonment of the
responsibility we have to all individuals with any renal
abnormality, be it proteinuria, decreased GFR, or whatever.
Obviously, the relatively blunt tools (urinalysis, eGFR) to
detect them need to be improved, but cannot be abandoned.
In the meantime, we must move on using the available tools.
To quote a founding father of medical statistics, Major
Greenwood (1680–1949), ‘The scientific purist, who will wait
for medical statistics until they are ontologically exact, is no
wiser than Horace’s rustic waiting for the river to flow away
before crossing.’26 The KDOQI classification has helped us
cross the river. It is now our responsibility to make the
crossing ‘safer’ in the future. Any effort to redesign the
classification must be data driven and deliberate. KDIGO has
undertaken this new challenge. There is no need for a rush to
judgment.
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